Home Exercise for Individuals with Neurodegenerative Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-13

Study Completion Date

2027-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to address the need for targeted therapeutic interventions for impairments that impact walking in related neurodegenerative diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Exercise on Individuals With Parkinson's Disease

NCT00591344

Parkinson's Disease

COMPLETED NA

Exercise to Improve Sleep in Parkinson's Disease

NCT05644327

Parkinson Disease

RECRUITING NA

Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

NCT06088355

Parkinson Disease Movement Disorders Neurodegeneration

RECRUITING NA

Physical Therapy and Cognitive Decline

NCT04012086

Parkinson Disease Cognitive Impairment

COMPLETED NA

Exercise Dosing Trial for Individuals With Parkinson's Disease

NCT02676804

Parkinsons Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will inform clinicians in quantitatively assessing baseline disease severity, selectively applying the appropriate exercise to the disease pathology, and measuring efficacy of the exercise intervention.

As part of this overall goal, the aims are to:

A. Determine feasibility of remotely supervised exercise programs. B. Optimize remote outcome measures for clinical monitoring and towards future clinical trials.

C. Measure changes in balance and walking post intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurodegenerative Diseases Leukodystrophy Ataxia LBSL Leukoencephalopathy with Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder) Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation Cerebellar Ataxia Adrenomyeloneuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Pre-test post-test design. Based on pre-test assessments participants will be instructed in an individualized exercise program. Participants will participate in 18 hours of remotely supervised and home practice exercises.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Home exercise

Individually designed home exercise program

Group Type EXPERIMENTAL

Home exercise

Intervention Type BEHAVIORAL

Exercise to address limitations impacting walking

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Home exercise

Exercise to address limitations impacting walking

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The eligibility criteria for males is X-linked adrenoleukodystrophy as determined by biochemical determination or genetic testing.
* The eligibility criteria for females is X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis.
* The Leukoenceophalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion is a confirmed DARS2 mutation through genetic analysis.
* For people with cerebellar ataxia, people with diagnoses of cerebellar damage from stroke, tumor or degeneration will be included. Those with a genetically confirmed cerebellar disorder will be asked to provide their genetic testing to note their particular type of ataxia.
* We will also include patients with other neurodegenerative diseases similar to these disorders as determined by chart review and clinical exam.

Healthy Volunteers

* Able to stand for 30 seconds without upper extremity support
* Ambulatory (including use of a cane or a walker)
* Able to walk for 2 minutes

Exclusion Criteria

* Other medical or psychological conditions which in the clinical judgement of the investigator would interfere with acquiring the study information or performing the exercises safely including but not limited to:

Uncontrolled hypertension, orthopedic conditions, diabetes, seizure disorder, peripheral vestibular loss, severe aphasia, dementia, pregnancy

Minimum Eligible Age

5 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes